Literature DB >> 27578111

Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes.

Ida Azizkhanian1, Olgica Trenchevska2, Yara Bashawri3, Jiaqi Hu1, Juraj Koska4, Peter D Reaven4, Randall W Nelson2, Dobrin Nedelkov2, Hussein N Yassine5.   

Abstract

BACKGROUND: Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known.
OBJECTIVE: Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes.
METHODS: Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes.
RESULTS: Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group.
CONCLUSION: The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.
Copyright © 2016 National Lipid Association. All rights reserved.

Entities:  

Keywords:  Apolipoprotein A-II; Diabetes; Mass spectrometry; Oxidations

Mesh:

Substances:

Year:  2016        PMID: 27578111      PMCID: PMC5195850          DOI: 10.1016/j.jacl.2016.03.001

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  22 in total

Review 1.  Mass spectrometric immunoassay revisited.

Authors:  Randall W Nelson; Chad R Borges
Journal:  J Am Soc Mass Spectrom       Date:  2011-03-08       Impact factor: 3.109

2.  In vitro activation of the enzymic activity of hepatic lipase by apoA-II.

Authors:  C E Jahn; J C Osborne; E J Schaefer; H B Brewer
Journal:  FEBS Lett       Date:  1981-08-31       Impact factor: 4.124

Review 3.  The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function.

Authors:  J P Segrest; M K Jones; H De Loof; C G Brouillette; Y V Venkatachalapathi; G M Anantharamaiah
Journal:  J Lipid Res       Date:  1992-02       Impact factor: 5.922

4.  ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance.

Authors:  J C Escolà-Gil; J Julve; A Marzal-Casacuberta ; J Ordóñez-Llanos; F González-Sastre; F Blanco-Vaca
Journal:  J Lipid Res       Date:  2001-02       Impact factor: 5.922

Review 5.  Apolipoprotein A-II: evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis.

Authors:  Dick C Chan; Theodore W K Ng; Gerald F Watts
Journal:  Ann Med       Date:  2011-04-18       Impact factor: 4.709

Review 6.  Diabetes, oxidative stress, and antioxidants: a review.

Authors:  A C Maritim; R A Sanders; J B Watkins
Journal:  J Biochem Mol Toxicol       Date:  2003       Impact factor: 3.642

7.  Contrasting in vivo effects of murine and human apolipoprotein A-II. Role of monomer versus dimer.

Authors:  E L Gong; L J Stoltfus; C M Brion; D Murugesh; E M Rubin
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

8.  Mass spectrometric immunoassay.

Authors:  R W Nelson; J R Krone; A L Bieber; P Williams
Journal:  Anal Chem       Date:  1995-04-01       Impact factor: 6.986

9.  Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice.

Authors:  C C Hedrick; L W Castellani; C H Warden; D L Puppione; A J Lusis
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

10.  Serum amyloid a truncations in type 2 diabetes mellitus.

Authors:  Hussein N Yassine; Olgica Trenchevska; Huijuan He; Chad R Borges; Dobrin Nedelkov; Wendy Mack; Naoko Kono; Juraj Koska; Peter D Reaven; Randall W Nelson
Journal:  PLoS One       Date:  2015-01-21       Impact factor: 3.240

View more
  4 in total

1.  A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins.

Authors:  Valentin Blanchard; Damien Garçon; Catherine Jaunet; Kevin Chemello; Stéphanie Billon-Crossouard; Audrey Aguesse; Aya Garfa; Gilles Famchon; Amada Torres; Cédric Le May; Matthieu Pichelin; Edith Bigot-Corbel; Gilles Lambert; Bertrand Cariou; Samy Hadjadj; Michel Krempf; Kalyane Bach-Ngohou; Mikaël Croyal
Journal:  J Lipid Res       Date:  2020-05-13       Impact factor: 5.922

Review 2.  Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes.

Authors:  Dobrin Nedelkov
Journal:  Proteomes       Date:  2017-10-15

3.  The Human Proteoform Atlas: a FAIR community resource for experimentally derived proteoforms.

Authors:  Michael A R Hollas; Matthew T Robey; Ryan T Fellers; Richard D LeDuc; Paul M Thomas; Neil L Kelleher
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

Review 4.  Apolipoprotein A-II, a Player in Multiple Processes and Diseases.

Authors:  Gabriela Florea; Irina Florina Tudorache; Elena Valeria Fuior; Radu Ionita; Madalina Dumitrescu; Ioana Madalina Fenyo; Violeta Georgeta Bivol; Anca Violeta Gafencu
Journal:  Biomedicines       Date:  2022-07-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.